Correspondence 0001962738-24-000022 from CASI Pharmaceuticals, Inc. (CASI) (CIK 0001962738) (CASIF)
CASI Pharmaceuticals, Inc. (CASI) (CIK 0001962738)
Date: May 9, 2024 · CIK: 0001962738 · Accession: 0001962738-24-000022
AI Filing Summary & Sentiment
File numbers found in text: 333-279096
Letter
CASI PHARMACEUTICALS, INC.
1701-1702, China Central Office Tower 1
No. 81 Jianguo Road Chaoyang District
Beijing, 100025
People’s Republic of China
May 9, 2024
Via Edgar
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Tim Buchmiller
Re:CASI Pharmaceuticals, Inc.
Registration Statement on Form F-3
Filed May 3, 2024
File No. 333-279096
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned respectfully requests that the effective date of the above-referenced Registration Statement (the “Registration Statement”) be accelerated so that the same will become effective on May 10, 2024, at 4:00 p.m., Eastern Daylight Time, or as soon thereafter as is practicable.
Please contact Michael Penney of Arnold & Porter Kaye Scholer LLP via telephone at (212) 836-7426 or via e-mail (Michael.Penney@arnoldporter.com) with any questions and please notify him when this request for acceleration has been granted.
Very truly yours,
CASI Pharmaceuticals, Inc.
Show Raw Text
CORRESP
1
filename1.htm
CASI PHARMACEUTICALS, INC.
1701-1702, China Central Office Tower 1
No. 81 Jianguo Road Chaoyang District
Beijing, 100025
People’s Republic of China
May 9, 2024
Via Edgar
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Tim Buchmiller
Re:CASI Pharmaceuticals, Inc.
Registration Statement on Form F-3
Filed May 3, 2024
File No. 333-279096
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned respectfully requests that the effective date of the above-referenced Registration Statement (the “Registration Statement”) be accelerated so that the same will become effective on May 10, 2024, at 4:00 p.m., Eastern Daylight Time, or as soon thereafter as is practicable.
Please contact Michael Penney of Arnold & Porter Kaye Scholer LLP via telephone at (212) 836-7426 or via e-mail (Michael.Penney@arnoldporter.com) with any questions and please notify him when this request for acceleration has been granted.
Very truly yours,
CASI Pharmaceuticals, Inc.
By: /s/ Wei-Wu He __________________________
Name: Dr. Wei-Wu He
Title: Chief Executive Officer and Chairman of the Board of
Directors